

September 29, 2026

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai-400051

BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

Ref: Regulation 30 read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Sub: Proceedings of the 33rd Annual General Meeting ("AGM") of Orchid Pharma Limited ("the Company") held on September 29, 2026

Dear Sir/Madam,

With reference to the captioned subject and in accordance with Regulation 30 read with Schedule III, Para A Part A of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, please find enclosed herewith Summary Proceedings of 33rd Annual General Meeting of the Company held on September 29, 2026, commenced at 12:00 Noon (IST) and concluded at 12:43 P.M. (IST).

The same is also available on the official website of the Company at <https://www.orchidpharma.com/investors>.

Kindly take the above on your records.

Thanking you,

For **Orchid Pharma Limited**

KAPIL

DAYYA

Digitally signed by
KAPIL DAYYA
Date: 2026.09.29
18:27:20 +05'30'

Kapil Dayya

Company Secretary and Compliance Officer

Mem. No. F10698

Encl.: as above

Registered Office:

Orchid Pharma Limited
Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate,
Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India.

Corporate Office:

15th Floor, Tower 1, DLF Corporate Greens, Sector 74A,
Gurugram - 122004, Haryana, India

Summary Proceedings of the 33rd Annual General Meeting of Orchid Pharma Limited held today i.e. Tuesday, September 29, 2026 at 12:00 Noon (IST) through Video Conference ("VC")/ Other Audio-Visual Means ("OAVM")

PRESENT THROUGH VIDEO CONFERENCING		Location
Mr. Manish Dhanuka	Managing Director	Gurugram
Mr. Arjun Dhanuka	Whole Time Director	Gurugram
CA (Dr.) Manoj Kumar Goyal	Independent Director and Chairman of the Audit Committee and nominated member of Stakeholders Relationship Committee and Nomination and Remuneration Committee	Noida
Ms. Shubha Singh	Independent Woman Director	Noida
Ms. Tanu Singla	Independent Woman Director	New Delhi
IN ATTENDANCE		
Mr. Kapil Dayya	Company Secretary & Compliance Officer	Gurugram
INVITEES		
Mr. Sunil Kumar Gupta	Chief Financial Officer	
Mr. Nishant Dalal	Vice-President Finance	
Mr. Sudesh Choraria	Authorized Representative of M/s. Singhi & Co., Statutory Auditor	
Mr. N. Ramanathan	Authorized Representative of M/s. S. Dhanapal & Associates LLP, Secretarial Auditor	
Mr. Muthukumaran	Partner, Practising Company Secretary, M/s. Muthukuman & Associates, Scrutinizer	

The 33rd Annual General Meeting ("AGM") of the Members of Orchid Pharma Limited ("the Company") held on Tuesday, September 29, 2026 at 12:00 Noon (IST) through Video Conferencing ("VC")/ Other Audio Visual Means ("OAVM") at the deemed venue; Registered Office of the Company.

Members present through VC/OAVM: 32

Mr. Kapil Dayya, Company Secretary welcomed the members and briefed certain procedural and technical information regarding the participation and voting by the Members through VC/OAVM at the meeting.

Mr. Manish Dhanuka, Managing Director of the Company welcomed the members and introduced the Board of Directors and attendees, who attended the meeting through Video Conferencing. He further informed the members that Mr. Ram Gopal Agarwal, Non-Executive Director cum Chairman of the Board of Directors, Mr. Mridul Dhanuka, Whole-Time Director and Dr. Dharam Vir, Independent Director, had sought leave of absence from the meeting.

The Managing Director also recorded the attendance of Mr. Sunil Kumar Gupta, Chief Financial Officer, Mr. Nishant Dalal, Vice-President Finance, M/s. Singhi & Co., Statutory Auditors, M/s. S Dhanapal & Associates LLP, Secretarial Auditors of the Company and M/s. P Muthukumaran & Associates, Scrutinizer at the AGM.

Thereafter, given the absence of Mr. Ram Gopal Agarwal from the meeting and pursuant to Articles of Association of the Company read with Secretarial Standard- 2 issued by the Institute of Company Secretaries of India, Mr. Manish Dhanuka was appointed as the Chairman of the AGM.

The Chairman confirmed the presence of requisite quorum and called the meeting to order.

Registered Office:

Orchid Pharma Limited
Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate,
Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India.

Corporate Office:

15th Floor, Tower 1, DLF Corporate Greens, Sector 74A,
Gurugram - 122004, Haryana, India

The Notice of AGM dated September 07, 2026 was taken as read and the Chairman delivered his speech highlighting Company's journey throughout the Financial Year 2025-26 with some financial insights and the macro-economic outlook.

The Company Secretary on the instructions of the Chairman informed the members that the Auditors' Report on Standalone Financial Statements of the Company for the Financial Year ended March 31, 2026 does not contain any qualification. However, there are certain qualifications made by Statutory Auditors in the Consolidated Auditor's Report, which along with the management's response were included in the statement on Impact of Audit Qualifications (for Audit reports with modified opinion) which forms part of Annual Report.

The Members were also informed about the comments/remarks of the Secretarial Auditors of the Company in their Report issued for the Financial Year 2025-26 along with the Management response included in the Board's Report for the same Financial Year.

Thereafter, the Company Secretary with the permission of chairman read out the businesses, as set out in the Notice convening the 33rd Annual General Meeting, for Members' consideration and approval:

S. No.	Resolution	Type of Resolution
1.	Adoption of the Revised financial statements, including the Consolidated financial statements for the financial year ending March 31, 2026, including the report of the Board of Directors and auditors thereon.	Ordinary Resolution
2.	Appointment of Mr. Mridul Dhanuka (DIN: 00199441) Whole-Time Director of the Company, who retires by rotation and being eligible, offers himself for reappointment.	Ordinary Resolution
3.	Ratification of remuneration of the Cost Auditor of the Company for the Financial Year 2026-27.	Ordinary Resolution
4.	*Approval for Material Related Party Transactions with M/s. Otsuka Chemical (India) Private Limited.	Ordinary Resolution
5.	Appointment of Mr. Arjun Dhanuka (DIN:00454689) as Whole-time Director of the Company and payment of remuneration to him (earlier designated as Non-Executive, Non-Independent Director)	Special Resolution

**Since Mr. Manish Dhanuka was interested in the agenda item, he stepped down as Chairman and nominated CA (Dr.) Manoj Kumar Goyal, Independent Director to Chair the AGM to transact the business i.e. Item No. 4. Post transacting the said business, Mr. Manish Dhanuka resumed the Chair and proceeded with the AGM.*

Thereafter, the Company Secretary explained the e-voting procedure to members in detail and requested to exercise their right to cast vote through e-voting at the AGM, in case they have not, during the remote e-voting period.

The members who had registered themselves as speaker shareholders were invited to express their views and queries raised by them were suitably replied and requests raised/ suggestions given, were taken on report by the Management. Further, the Company Secretary informed the Members to send their questions/clarifications, if any, to email id: investorrelations@orchidpharma.com or cs@orchidpharma.com.

Thereafter, the Members were informed that the e-voting window would be kept open for 15 minutes and requested the Members who had not cast their vote to do the same before the said time. It was further informed that the e-voting results along with Scrutinizer Report shall be declared within 2 working days of conclusion of this meeting and the same would be placed on the website of the Company and NSDL and will be submitted with the stock exchanges.

The Meeting concluded at 12:43 P.M. (IST) with the end of e-voting time.